- Home
- FEBO vs EQ Comparison
FEBO vs EQ Comparison
Compare FEBO & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEBO
- EQ
- Stock Information
- Founded
- FEBO 1993
- EQ 2017
- Country
- FEBO Hong Kong
- EQ United States
- Employees
- FEBO N/A
- EQ N/A
- Industry
- FEBO
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- FEBO
- EQ Health Care
- Exchange
- FEBO Nasdaq
- EQ Nasdaq
- Market Cap
- FEBO 12.6M
- EQ 12.2M
- IPO Year
- FEBO 2023
- EQ 2018
- Fundamental
- Price
- FEBO $0.99
- EQ $0.35
- Analyst Decision
- FEBO
- EQ Buy
- Analyst Count
- FEBO 0
- EQ 3
- Target Price
- FEBO N/A
- EQ $3.00
- AVG Volume (30 Days)
- FEBO 19.3K
- EQ 1.3M
- Earning Date
- FEBO 07-22-2025
- EQ 08-07-2025
- Dividend Yield
- FEBO N/A
- EQ N/A
- EPS Growth
- FEBO N/A
- EQ N/A
- EPS
- FEBO N/A
- EQ N/A
- Revenue
- FEBO $17,110,653.00
- EQ $30,406,000.00
- Revenue This Year
- FEBO N/A
- EQ N/A
- Revenue Next Year
- FEBO N/A
- EQ N/A
- P/E Ratio
- FEBO N/A
- EQ N/A
- Revenue Growth
- FEBO 11.58
- EQ N/A
- 52 Week Low
- FEBO $0.82
- EQ $0.27
- 52 Week High
- FEBO $15.48
- EQ $1.50
- Technical
- Relative Strength Index (RSI)
- FEBO 45.49
- EQ 51.20
- Support Level
- FEBO $0.82
- EQ $0.29
- Resistance Level
- FEBO $1.26
- EQ $0.48
- Average True Range (ATR)
- FEBO 0.10
- EQ 0.05
- MACD
- FEBO -0.01
- EQ 0.01
- Stochastic Oscillator
- FEBO 37.44
- EQ 38.05
About FEBO Fenbo Holdings Limited
Fenbo Holdings Ltd is a company engaged in producing premium personal care electric appliances, principally electrical hair styling products such as straighteners, curlers, trimmers, etc., and toy products to overseas markets. It manufactures and sells products such as Straightener, Mini Straightener, and Curling Iron.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.